Ayhan E, Araç E, Aslan Ö. Isotretinoin does not alter VEGF-A and VEGF-C levels: do retinoids behave differently in dose-dependent and/or
in vivo/in vitro conditions?
Cutan Ocul Toxicol 2020;
39:328-331. [PMID:
32722957 DOI:
10.1080/15569527.2020.1802743]
[Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/23/2022]
Abstract
BACKGROUND
It is seen that various forms of retinoids have different results on VEGF-A and VEGF-C levels when tested at different dosages, in different diseases and under different conditions such as in vivo or in vitro.
OBJECTIVE
To evaluate the effects of isotretinoin on VEGF-A and VEGF-C levels in humans.
METHODS
Blood samples at the third month of the patient group and blood samples of the control group were compared in terms of VEGF-A and VEGF-C concentrations.
RESULTS
No statistically significant difference was observed between the patient group and the control group in terms of VEGF-A and VEGF-C levels.
LIMITATIONS
Most of the patients discontinued treatment and could not reach the required number, the study was converted to case-control.
CONCLUSIONS
We think that 0.5 mg/kg/day isotretinoin has no effect on blood concentrations of VEGF-A and VEGF-C in humans. Therefore, there is a need for studies using isotretinoin in different doses and durations in humans in order to better evaluate its effects.
Collapse